Tiziana Announces Last Patient In Ongoing Phase 2a Clinical Trial Receives First Dose Of Intranasal Foralumab For Treatment Of Non-Active Secondary Progressive Multiple Sclerosis; Topline Data Expected In Late Q3/Early Q4 Of 2026

뉴스 본문을 불러오고 있어요.

Tiziana Announces Last Patient In Ongoing Phase 2a Clinical Trial Receives First Dose Of Intranasal Foralumab For Treatment Of Non-Active Secondary Progressive Multiple Sclerosis; Topline Data Expected In Late Q3/Early Q4 Of 2026 | 웨이프 WAPE

Tiziana Announces Last Patient In Ongoing Phase 2a Clinical Trial Receives First Dose Of Intranasal Foralumab For Treatment Of Non-Active Secondary Progressive Multiple Sclerosis; Topline Data Expected In Late Q3/Early Q4 Of 2026

기사 요약

관련 종목

댓글 —